Integra Lifesciences Holdings (STU:IL3) Selling, General, & Admin. Expense: €599 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:IL3 Integra Lifesciences Holdings Corp STU:IL3
74 GF Score
Price €17.30
GF Value €20.57
Valuation Modestly Undervalued
! 11 Warning Signs
View Full Analysis

What is Integra Lifesciences Holdings Selling, General, & Admin. Expense?

Integra Lifesciences Holdings STU:IL3 +6.13% 74 Selling, General, & Admin. Expense is €599 Mil as of Mar. 2026. GuruFocus rates STU:IL3 with a GF Score™ of 74/100 and a GF Value™ of €20.57 (Modestly Undervalued). The stock has 11 warning signs investors should review.

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Integra Lifesciences Holdings's selling, general, & admin. expense for the three months ended in Mar. 2026 was €154 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Mar. 2026 was €599 Mil.


Integra Lifesciences Holdings  (STU:IL3) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Integra Lifesciences Holdings Selling, General, & Admin. Expense Related Terms


Integra Lifesciences Holdings Selling, General, & Admin. Expense Historical Data

* Premium members only.

The historical data trend for Integra Lifesciences Holdings's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Integra Lifesciences Holdings Selling, General, & Admin. Expense Chart

Integra Lifesciences Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Selling, General, & Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 564.14 581.80 602.14 684.72 597.54

Integra Lifesciences Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 167.89 155.97 144.03 144.55 154.17

STU:IL3 vs ATEC, AHCO, INSP: Selling, General, & Admin. Expense Comparison

For the Medical Devices subindustry, Integra Lifesciences Holdings's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Integra Lifesciences Holdings Selling, General, & Admin. Expense vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Integra Lifesciences Holdings's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Integra Lifesciences Holdings's Selling, General, & Admin. Expense falls into.


STU:IL3
74GF Score
Integra Lifesciences Holdings Corp STU:IL3
Selling, General, & Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Integra Lifesciences Holdings Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €599 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Selling, General, & Admin. Expense of €599 Mil mean?
Integra Lifesciences Holdings (STU:IL3) has a Selling, General, & Admin. Expense of €599 Mil as of Mar. 2026. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Integra Lifesciences Holdings and its competitors.
Is Integra Lifesciences Holdings' Selling, General, & Admin. Expense too high?
Integra Lifesciences Holdings' current Selling, General, & Admin. Expense is €599 Mil. Overall, Integra Lifesciences Holdings has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Integra Lifesciences Holdings' Selling, General, & Admin. Expense compare to ATEC and AHCO?
Integra Lifesciences Holdings' Selling, General, & Admin. Expense of €599 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Medical Devices & Instruments company?
A good Selling, General, & Admin. Expense depends on the Medical Devices & Instruments industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Integra Lifesciences Holdings and its competitors. Integra Lifesciences Holdings's current Selling, General, & Admin. Expense is €599 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integra Lifesciences Holdings stock overvalued right now?
Based on GuruFocus' analysis, Integra Lifesciences Holdings (STU:IL3) is currently considered Modestly Undervalued. The stock's GF Value™ is €20.57, compared to a current price of €17.30 — trading 15.9% below its estimated fair value. The current Selling, General, & Admin. Expense is €599 Mil. Integra Lifesciences Holdings' overall GF Score™ is 74/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For Integra Lifesciences Holdings (STU:IL3), the current Selling, General, & Admin. Expense is €599 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Integra Lifesciences Holdings (STU:IL3) Overvalued in 2026?

Based on GuruFocus' analysis, Integra Lifesciences Holdings stock appears to be undervalued. The current stock price of €17.30 is trading 15.9% below its estimated GF Value™ of €20.57. GuruFocus considers Integra Lifesciences Holdings to be Modestly Undervalued.

Key valuation signals for STU:IL3:

  • Selling, General, & Admin. Expense: €599 Mil
  • GF Value™: €20.57 vs. price of €17.30 (15.9% below fair value)
  • GF Score™: 74/100 with 11 warning signs

No single metric tells the full story. See the STU:IL3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Integra Lifesciences Holdings Business Description

Other Exchanges IART:USA
Address 1100 Campus Road, Princeton, NJ, USA, 08540
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.
74GF Score

Get the complete analysis for STU:IL3

Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€17.30
Price
€20.57
GF Value